Kalaris Therapeutics Inc
KLRSHealthcare|Biotechnology|US
$2.42
+0.06 (+2.54%)
DCF Value
$6.25
Tangible Book / Share
$2.42
Cash / Share
$3.93
Next Earnings Report
Nov 11, 2026
EPS est. -$0.52
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Recent Press Releases
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Aug 31, 2026 · GlobeNewsWire
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 11, 2026 · GlobeNewsWire